| review article | Q7318358 |
| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P2093 | author name string | Zakia Bibi | |
| P2860 | cites work | Pharmacokinetic Drug Interactions with Oral Contraceptives | Q22305837 |
| Cytochrome P4502C9: an enzyme of major importance in human drug metabolism | Q24683497 | ||
| Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of [...] | Q28115162 | ||
| Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae | Q28332545 | ||
| Torsades de pointes occurring in association with terfenadine use | Q28334377 | ||
| Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake | Q45215557 | ||
| Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice | Q48809052 | ||
| Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. | Q51018598 | ||
| Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. | Q51530884 | ||
| Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. | Q51577607 | ||
| Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. | Q51578907 | ||
| Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. | Q51590352 | ||
| The erythromycin breath test predicts the clearance of midazolam. | Q51614889 | ||
| Mechanisms of ethanol-drug-nutrition interactions. | Q51646112 | ||
| Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. | Q51743867 | ||
| Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. | Q51818926 | ||
| Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. | Q53809592 | ||
| Ethanol enhances the hemodynamic effects of felodipine. | Q54339719 | ||
| Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. | Q55060683 | ||
| Loss of analgesic effect of morphine due to coadministration of rifampin | Q56832359 | ||
| Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities | Q59153257 | ||
| Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism | Q61794937 | ||
| Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture | Q67532013 | ||
| Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin | Q68045940 | ||
| Differential inhibition of individual human liver cytochromes P-450 by cimetidine | Q68063454 | ||
| Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene | Q68397000 | ||
| The microsomal ethanol oxidizing system and its interaction with other drugs, carcinogens, and vitamins | Q68766357 | ||
| Erythromycin-cyclosporin interaction | Q68883421 | ||
| Clinical significance of the sparteine/debrisoquine oxidation polymorphism | Q69373690 | ||
| Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences | Q70591704 | ||
| 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes | Q70639652 | ||
| Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin | Q70766724 | ||
| Phenytoin toxicity due to concomitant antituberculosis therapy | Q70990937 | ||
| Severe carbamazepine toxicity induced by concurrent erythromycin therapy | Q71458023 | ||
| Interactions and drug-metabolizing enzymes | Q71550886 | ||
| Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin | Q71650801 | ||
| The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism | Q71731666 | ||
| Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes | Q71812126 | ||
| In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices | Q71812186 | ||
| Ethanol and acetaldehyde metabolism: past, present, and future | Q71841556 | ||
| Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update | Q71841578 | ||
| Diltiazem does not always increase blood cyclosporin concentration | Q71850230 | ||
| Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation | Q72223807 | ||
| Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine | Q72467721 | ||
| Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation | Q72545136 | ||
| Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia | Q72564540 | ||
| Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin | Q72693322 | ||
| Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity | Q72703173 | ||
| Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences | Q72793332 | ||
| Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs | Q73064221 | ||
| Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man | Q73947667 | ||
| Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin | Q73949924 | ||
| Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants | Q74525214 | ||
| Pharmacokinetic drug interactions with anti-ulcer drugs | Q77306655 | ||
| Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s | Q28610006 | ||
| Interactions Between Antipsychotic and Antihypertensive Drugs | Q33173690 | ||
| Defective N-oxidation of sparteine in man: A new pharmacogenetic defect | Q34053243 | ||
| Polymorphic hydroxylation of Debrisoquine in man. | Q34057031 | ||
| Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin | Q34241704 | ||
| Severe acetaminophen toxicity in a patient receiving isoniazid | Q34260561 | ||
| Erythromycin-induced carbamazepine toxicity: a continuing problem | Q34316480 | ||
| A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking | Q34418056 | ||
| Drug interaction between propafenone and metoprolol | Q34420988 | ||
| The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies | Q34447852 | ||
| Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence | Q34452996 | ||
| Update: clinically significant cytochrome P-450 drug interactions | Q34456931 | ||
| Grape fruit juice-drug interactions | Q34479869 | ||
| Effect of smoking on theophylline disposition | Q34534103 | ||
| Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole | Q34579242 | ||
| Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations | Q34695612 | ||
| Clinically important drug interactions with anticoagulants. An update | Q34734558 | ||
| Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. | Q34735311 | ||
| Drug interactions with grapefruit juice | Q34742609 | ||
| Clinical singgnificance of interactions with antifungal agents | Q35225764 | ||
| Pharmacokinetic drug interactions of macrolides | Q35759081 | ||
| Characterization of human cytochrome P450 enzymes | Q35890693 | ||
| Pharmacokinetic drug interactions with rifampicin | Q35981437 | ||
| Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes | Q36093758 | ||
| Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship | Q36094166 | ||
| Molecular genetics of the debrisoquin-sparteine polymorphism | Q36522041 | ||
| Omeprazole drug interaction studies | Q36890310 | ||
| Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme | Q37314759 | ||
| Alcohol and drug interactions | Q37610909 | ||
| The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature | Q37632095 | ||
| Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal | Q37782957 | ||
| The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms | Q37911387 | ||
| The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects | Q37924766 | ||
| Selective Serotonin Reuptake Inhibitors: Pharmacologic Profiles and Potential Therapeutic Distinctions | Q38573611 | ||
| Genetic polymorphism of S-mephenytoin hydroxylation | Q38692055 | ||
| Pharmacokinetic interactions of cimetidine 1987. | Q39662361 | ||
| Role of tobacco smoking in pharmacokinetics | Q39723934 | ||
| Pharmacokinetic interaction between rifampin and zidovudine | Q39866285 | ||
| Drug interactions with cimetidine | Q40329702 | ||
| P450 inhibitors of use in medical treatment: focus on mechanisms of action | Q40379770 | ||
| Macrolide antibacterials. Drug interactions of clinical significance | Q40423079 | ||
| Recent Advances: the Cytochrome P450 Enzymes | Q40475823 | ||
| The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature | Q40484461 | ||
| Pharmacogenetics and drug metabolism of newer antidepressant agents. | Q40564994 | ||
| Clinically significant drug interactions with antituberculosis agents | Q40587502 | ||
| Pharmacokinetic drug interactions with antimicrobial agents | Q40720380 | ||
| Hypertension and endstage renal disease | Q40757473 | ||
| Drug interactions of clinical significance with opioid analgesics | Q40895607 | ||
| Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. | Q40932838 | ||
| Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update | Q40949311 | ||
| Cigarette smoking and clinically significant drug interactions | Q40952943 | ||
| Newer antidepressants and the cytochrome P450 system | Q40976263 | ||
| Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. | Q41027208 | ||
| The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions | Q41030442 | ||
| Drug interactions with antiviral drugs | Q41066477 | ||
| The emerging role of cytochrome P450 3A in psychopharmacology | Q41071277 | ||
| Cytochrome P450 isozymes and antiepileptic drug interactions | Q41112031 | ||
| Drug interactions with azithromycin and the macrolides: an overview | Q41119734 | ||
| Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole | Q41128197 | ||
| Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. | Q41143923 | ||
| Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. | Q41143946 | ||
| Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. | Q41143951 | ||
| Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. | Q41173261 | ||
| New applications of bacterial systems to problems in toxicology. | Q41188301 | ||
| Pharmacokinetic interactions of the new antiepileptic drugs | Q41192725 | ||
| Clinically significant drug interactions with cyclosporin. An update | Q41201529 | ||
| Pharmacokinetics and drug interactions: update for new antipsychotics | Q41240756 | ||
| Susceptibility to alcohol-related liver injury | Q41281855 | ||
| Drug interactions of macrolides: emphasis on dirithromycin | Q41380268 | ||
| Drug interactions with proton pump inhibitors | Q41428950 | ||
| Clinically significant drug interactions with new immunosuppressive agents | Q41440255 | ||
| Drug-mediated inactivation of cytochrome P450. | Q41555359 | ||
| Pharmacokinetic interactions between alcohol and other drugs | Q41565312 | ||
| A review of enzyme induction of warfarin metabolism with recommendations for patient management | Q41607931 | ||
| Role of cytochrome P450 enzymes in drug-drug interactions. | Q41619409 | ||
| Cytochrome P-450 3A: interactions with dermatologic therapies | Q41641136 | ||
| Drug interactions in human neuropathic pain pharmacotherapy | Q41670759 | ||
| Drug interactions of clinical significance with selective serotonin reuptake inhibitors | Q41682186 | ||
| Interactions between tacrolimus and antimicrobial agents. | Q41683257 | ||
| Cytochrome P450: new nomenclature and clinical implications | Q41691948 | ||
| In vitro approaches to predicting drug interactions in vivo. | Q41692688 | ||
| Erythromycin: drug interactions | Q41704719 | ||
| Systemic antifungal agents. Drug interactions of clinical significance | Q41725883 | ||
| Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers | Q42122933 | ||
| Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. | Q42226492 | ||
| Clinically relevant drug-drug interactions in oncology | Q42284655 | ||
| Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs | Q42552393 | ||
| Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily | Q43422277 | ||
| Expression of cytochrome P-450 enzymes in cultured human hepatocytes | Q44049518 | ||
| Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. | Q44898021 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human nutrition | Q2602563 |
| P304 | page(s) | 27 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Nutrition and Metabolism | Q15752980 |
| P1476 | title | Role of cytochrome P450 in drug interactions | |
| P478 | volume | 5 |
| Q46091244 | A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. |
| Q53801573 | A study on the effect of cimetidine and L-carnitine on myoglobinuric acute kidney injury in male rats. |
| Q64119158 | Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid |
| Q50281847 | CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem |
| Q33768358 | Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4. |
| Q92054763 | Curcumin effect on cancer cells' multidrug resistance: An update |
| Q92552975 | Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline |
| Q37442618 | Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers |
| Q97588879 | Development of a metabolically stable topoisomerase I poison as anticancer agent |
| Q39501603 | Distribution of CYP2C19*2 and CYP2C19*3 polymorphisms in Venezuelan populations with different admixture |
| Q28475862 | Does the clock make the poison? Circadian variation in response to pesticides |
| Q85979393 | Effect of ciprofloxacin and grapefruit juice on oral pharmacokinetics of riluzole in Wistar rats |
| Q46930998 | Effect of commonly used organic solvents on aldehyde oxidase-mediated vanillin, phthalazine and methotrexate oxidation in human, rat and mouse liver subcellular fractions |
| Q86006407 | Effects of 2,2',4,4'-tetrabromodiphenyl ether (BDE47) on the enzymes of phase I (CYP2B1/2) and phase II (SULT1A and COMT) metabolism, and differences in the action of parent BDE-47 and its hydroxylated metabolites, 5-OH-BDE-47 and 6-OH-BDE47, on ste |
| Q54361453 | Effects of enrofloxacin on cytochromes P4501A and P4503A in Carassius auratus gibelio (crucian carp). |
| Q84607160 | Effects of ephedra water decoction and cough tablets containing ephedra and liquorice on CYP1A2 and the pharmacokinetics of theophylline in rats |
| Q84483077 | Effects of fluoroquinolones on CYP4501A and 3A in male broilers |
| Q39178477 | Effects of norfloxacin on hepatic genes expression of P450 isoforms (CYP1A and CYP3A), GST and P-glycoprotein (P-gp) in Swordtail fish (Xiphophorus Helleri). |
| Q57871328 | Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain |
| Q38862327 | Enhanced Metabolizing Activity of Human ES Cell-Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics |
| Q85553965 | Ephedra water decoction and cough tablets containing ephedra and liquorice induce CYP1A2 but not CYP2E1 hepatic enzymes in rats |
| Q42233351 | Even 'safe' medications need to be administered with care |
| Q82466277 | Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation |
| Q82680399 | Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation |
| Q87211259 | Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions |
| Q40226025 | Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly |
| Q90749633 | Food-Drug Interaction between the Adlay Bran Oil and Drugs in Rats |
| Q98238804 | Gold Nanoparticles Perturb Drug-Metabolizing Enzymes and Antioxidants in the Livers of Male Rats: Potential Impact on Drug Interactions |
| Q92890984 | Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction |
| Q35648962 | Hepatotoxicity of molecular targeted therapy |
| Q28240999 | Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders |
| Q101117560 | Impact of Transgenic Arabidopsis thaliana Plants on Herbicide Isoproturon Phytoremediation through Expressing Human Cytochrome P450-1A2 |
| Q122397436 | In silico screening for potential inhibitors from the phytocompounds of Carica papaya against Zika virus NS5 protein |
| Q87237318 | In vitro assessment of CYP1A2 and 2C9 inhibition potential of Withania somnifera and Centella asiatica in human liver microsomes |
| Q45306265 | Incorporating psychiatric pharmacogenetics into family practice |
| Q53735385 | Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy. |
| Q42672906 | Influence of three coccidiostats on the pharmacokinetics of florfenicol in rabbits |
| Q50850212 | Influence of tobacco smoke exposure on pharmacokinetics of ethyl alcohol in alcohol preferring and non-preferring rats. |
| Q35579544 | Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions |
| Q86629675 | Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship |
| Q47682758 | In vitro and in vivo cytochrome P450 3A enzyme inhibition by Aframomum melegueta and Denniettia tripetala extracts |
| Q60240219 | Kaempferol – A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements |
| Q39534069 | Ketoconazole, a cytochrome P(450) inhibitor can potentiate the antimalarial action of α/β arteether against MDR Plasmodium yoelii nigeriensis |
| Q58557345 | Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study |
| Q46587852 | Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305. |
| Q39000644 | Microsomal cytochrome P450 as a target for drug discovery and repurposing |
| Q64099168 | Network-based prediction of drug combinations |
| Q38053461 | Pharmacokinetics of macrolides in foals |
| Q38107023 | Pharmacophore modeling for ADME. |
| Q86314907 | Phenytoin-rifampin drug interaction in a hypoalbuminemic, renal failure patient: a complex clinical case |
| Q112579841 | Potential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga Halymenia durvillei (Rhodophyta) - A computational study |
| Q51738081 | Production of a New Plant-Based Milk from Adenanthera pavonina Seed and Evaluation of Its Nutritional and Health Benefits. |
| Q42643524 | Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates |
| Q45157771 | Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen |
| Q41955577 | Retraction: Role of cytochrome P450 in drug interactions |
| Q48313390 | Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. |
| Q46777015 | Selected Food/Herb-Drug Interactions: Mechanisms and Clinical Relevance. |
| Q91974324 | Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism |
| Q35185164 | Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis |
| Q44049123 | Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties |
| Q49248994 | The Role of Cytochromes P450 in Infection |
| Q55426998 | The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. |
| Q38849978 | The pathogenesis of drug-induced liver injury |
| Q47598246 | The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs |
| Q41675649 | Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases |
| Q88432627 | Transmucosal delivery of melatonin-encapsulated niosomes in a mucoadhesive gel |
| Q38250391 | Understanding and managing oral bioavailability: physiological concepts and patents |
| Q46430453 | Utility of a column-switching LC/MS/MS method in cytochrome P450 inhibition assays using human liver microsomes |
| Q96603404 | [BOMBAX COSTATUM EXTRACT ABROGATES PIROXICAM-MEDIATED HEPATIC AND GASTRIC TOXICITIES IN RATS] |
| Q87014352 | [Mechanism of hepatoprotective action of methionine and composition "Metovitan" against a background of antituberculosis drug administration to rats] |
| Q54624734 | [Risk of pharmacological interactions due to the co-administration of statins and cytochrome P450 isoenzyme 3A4-metabolized drugs: multicentre, crossover study]. |
Search more.